EPISODE · May 21, 2026 · 10 MIN
May 20, 2026 | Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI
from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group
Pfizer's 25-valent pneumococcal shot shows 8.8x–15x higher antibody levels vs. Prevnar 20 in Phase 2, advancing to Phase 3. BMS deploys Claude across 30,000+ employees in landmark pharma-AI deal. Lilly acquires Engage Bio for $202M. Tavneos linked to 20 deaths in Japan.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Prevnar 20, 25vPnC, pneumococcal vaccine, Bristol Myers Squibb, BMS, Anthropic, Claude, artificial intelligence, enterprise AI, Eli Lilly, Engage Biologics, Gilead Sciences, Yuhan, Amgen, Tavneos, avacopan, ImmunityBio, Anktiva, NMIBC, Parabilis, Relay Therapeutics, GHO Capital, CBC Group, PDUFA, Lilly, Novartis, Roche, Merck, Gilead, Regeneron
What this episode covers
Pfizer's 25-valent pneumococcal shot shows 8.8x–15x higher antibody levels vs. Prevnar 20 in Phase 2, advancing to Phase 3. BMS deploys Claude across 30,000+ employees in landmark pharma-AI deal. Lilly acquires Engage Bio for $202M. Tavneos linked to 20 deaths in Japan.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Prevnar 20, 25vPnC, pneumococcal vaccine, Bristol Myers Squibb, BMS, Anthropic, Claude, artificial intelligence, enterprise AI, Eli Lilly, Engage Biologics, Gilead Sciences, Yuhan, Amgen, Tavneos, avacopan, ImmunityBio, Anktiva, NMIBC, Parabilis, Relay Therapeutics, GHO Capital, CBC Group, PDUFA, Lilly, Novartis, Roche, Merck, Gilead, Regeneron
NOW PLAYING
May 20, 2026 | Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m